GZMO Message Board - Msg: 11273416

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jeffbas who wrote (91)	9/16/1999 3:03:00 PM
From: jeffbas	Read Replies (1) of 438

Key announcements: biz.yahoo.com biz.yahoo.com Key paragraph vis a vis ENMD: These animal studies suggest that the potency of aaATIII is at least comparable to that of angiostatin and endostatin, two other naturally occurring protein inhibitors of tumor angiogenesis previously described by Drs. Folkman and O'Reilly. Indeed, in characterizing the tumor regression achieved with aaATIII in the SK-NAS neuroblastoma animal model, the paper states, ''This same pattern of regression of established tumors has been demonstrated previously for human angiostatin and endostatin but required substantially higher and more frequent dosing.'' However, the optimal dosing regimens of all three compounds have not yet been determined in humans. I am told that there will be a conference call at 9 AM tomorrow at 212-346-0295.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next